- Partnering
with Dermagate to improve the health of women worldwide
- Working
toward qualification of an accreditation that will open more doors
worldwide
- A
promising year lays ahead with access to additional medical devices for
ETST and an accelerated-to-market certification process for Hygee
Earth Science Tech, Inc. (OTCQB: ETST), a biotech company
developing and marketing health-oriented products, has partnered with
Dermagate, a fast growing company specializing in the manufacturing of
dermatology and wound care products, to manufacture Hygee medical devices. A
recent press release (http://ibn.fm/wDFw5)
emphasizes that both companies share a concern for the health of women
worldwide, making them a natural fit in the production and distribution of this
self-sampling kit that allows women to test for sexually transmitted infections
(STIs) in the privacy of their own homes.
Hygee has already been proven successful in detecting
chlamydia. Testing for additional STIs and non-STI infections will be added
soon. The goal of the current medical device is to help reduce the overall
spread of chlamydia and help women avoid the dangerous complications of this
STI. By providing an affordable, discreet testing procedure, ETST is empowering
woman to take charge of their health. Dermagate is making it possible to
produce and distribute these kits worldwide.
Dermagate holds the necessary ISO 13485:2013 certifications
that will allow for distribution and has already begun the application process
for the new Medical Device Single Audit Program (MDSAP) certification of all of
its products, including Hygee. The MDSAP will soon replace the ISO 13485:2013
certification. Australia, Brazil, Canada, Japan and the United States are five
major markets that will soon adopt the new certification. The advantage of
MDSAP, which is also being considered by additional countries, is that one
accreditation covers all participating countries rather than having to earn a
new accreditation for every individual country.
Next year promises to be a productive one for ETST, as this
new partnership will give the company access to additional medical devices for
distribution. Certification for the distribution of Hygee in Canada is expected
to take place in January. Certification for distribution in various other
countries is anticipated in mid-2019. In addition to Hygee, two new
nutraceutical products are scheduled to be launched in the coming year.
“The volume of first-year sales for Hygee will probably be
far more than anticipated,” Gaétan Houle, president and CEO of PharmaGate Group
Inc. and Dermagate, stated in a news release. “We are not afraid of success. We
are able to scale the production to any level needed to meet the worldwide
market needs.”
For more information, visit the company’s website at www.EarthScienceTech.com
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
